Scientists launch biobank to unlock secrets of rare vasculitis
NCT ID NCT05364892
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting blood, urine, and fecal samples from 100 people with ANCA-associated vasculitis, a rare autoimmune disease. Researchers will follow participants for up to 5 years, tracking relapses and complications. The goal is to identify factors that predict disease flare-ups and improve long-term management.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict relapses and complications in ANCA vasculitis, leading to better, more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data and samples but does not test any new therapy, so it cannot directly improve health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Brest - Service de rhumatologie
RECRUITINGBrest, Brest, 29200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Can a new drug tame vasculitis with fewer side effects?
- Engineered immune cells take aim at autoimmune kidney diseases
- Could a diabetes drug shield kidneys from autoimmune attack?
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- New tool could predict who will suffer from steroid side effects